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Abstract
Introduction: Although hepatitis C virus (HCV) screening is recommended for all HIV-infected patients initiating antiretroviral
therapy, data on epidemiologic characteristics of HCV infection in resource-limited settings are scarce.
Methods: We searched PubMed and EMBASE for studies assessing the prevalence of HCV infection among HIV-infected
individuals in Africa and extracted data on laboratory methods used. Prevalence estimates from individual studies were
combined for each country using random-effects meta-analysis. The importance of study design, population and setting as well
as type of test (anti-HCV antibody tests and polymerase chain reactions) was examined with meta-regression.
Results: Three randomized controlled trials, 28 cohort studies and 121 cross-sectional analyses with 108,180 HIV-infected
individuals from 35 countries were included. The majority of data came from outpatient populations (55%), followed by blood
donors (15%) and pregnant women (14%). Based on estimates from 159 study populations, anti-HCV positivity prevalence
ranged between 3.3% (95% confidence interval (CI) 1.84.7) in Southern Africa and 42.3% (95% CI 4.180.5) in North Africa.
Study design, type of setting and age distribution did not influence this prevalence significantly. The prevalence of replicating
HCV infection, estimated from data of 29 cohorts, was 2.0% (95% CI 1.52.6). Ten studies from nine countries reported the HCV
genotype of 74 samples, 53% were genotype 1, 24% genotype 2, 14% genotype 4 and 9% genotypes 3, 5 or 6.
Conclusions: The prevalence of anti-HCV antibodies is high in HIV-infected patients in Africa, but replicating HCV infection is rare
and varies widely across countries.
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Introduction
Worldwide, four to five million HIV-infected individuals have
concomitant chronic hepatitis C virus (HCV) infection [1]. HIV
accelerates the progression of liver injury due to HCV,
including liver cirrhosis and hepatocellular carcinoma (HCC)
[2]. In the era of highly active antiretroviral therapy (ART),
HCV infection has become a major cause of death in HIV-
infected individuals in high-income countries [3,4]. The World
Health Organization (WHO) recommends that all HIV-infected
individuals be screened for HCV infection, ideally at pre-
sentation or before the initiation of ART [5]. These guidelines
are based on a wealth of data from high-income countries,
showing that HIV-infected patients, especially persons who
inject drugs (PWID) and men who have sex with men (MSM),
are at increased risk of HCV infection [6,7].
In resource-limited settings, data on the prevalence of HCV
infection in HIV-infected populations and its impact on long-
term clinical outcomes are limited. In particular, prevalence
estimates of HCV co-infection in African HIV programmes vary
widely across settings and are mainly based on studies that
used serological tests with low specificity [8]. For instance,
of 500 HIV-infected patients investigated for HCV infection
in Rakai, Uganda, 31 (6.2%) had a positive HCV-antibody
serology but no replicative HCV infection was found when
using polymerase chain reaction (PCR) [9]. Similar discrepan-
cies between HCV serology and PCR results were found in
pregnant women in Southern Africa and outpatients in West
Africa [10,11].
In settings with limited resources for health, HIV treatment
and care programmes must give priority to cost-effective
interventions. A thorough assessment of the prevalence of
HIV/HCV co-infection, including chronic active HCV infection
and the genotypes involved, is needed to guide screening
and treatment strategies [12]. We performed a systematic
review of the literature and a meta-analysis to synthesize the
prevalence of HCV-antibody positivity and model the pre-
valence of replicating HCV infection in HIV-infected individuals
in Africa.
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Methods
A protocol for this systematic review was written and reg-
istered with the International prospective register of sys-
tematic reviews (PROSPERO registration number CRD42015
016355) [13].The reporting of the review followed the PRISMA
guidelines [14].
Search strategy and study selection
We searched PubMed and EMBASE on 3 March 2016 for
studies assessing the prevalence of HCV-co-infection in HIV-
infected individuals in Africa. In PubMed, we combined free
text words and medical subject headings (MESH) describing
the study population and the outcome (see Supplementary
file). The PubMed search was adapted for EMBASE. We con-
sidered any type of study including randomized controlled
trials (RCTs), cohort studies and cross-sectional analyses that
included at least 20 HIV-infected patients. No language
restrictions were applied. We excluded studies that did not
describe the study population or the HCV tests used. If studies
reported estimates of the prevalence of HIV/HCV co-infection
for different population groups, each estimate was included
separately. If several articles reported on the same popula-
tion, we included the report with the most detailed descrip-
tion of the study population and type of diagnostic test used.
Two reviewers (TC and GW) independently selected studies
first based on titles and abstracts, and, in a second step, based
on the full text of potentially eligible articles.
Data extraction
Two independent reviewers (TC and GW) extracted data on
the study design, setting (urban, rural or both), type of
institution (teaching hospital, other hospital, health centre,
community, laboratory, prison), age categories (adults over
15 years, children, both), study population (outpatient, inpatient,
blood donors, pregnant women, community sample, special
populations) as well as on the characteristics of the HCV test per-
formed (type of test, description and commercial name). HCV
prevalence from serological tests, rapid point-of-care tests,
immunoblots and PCR was considered. Furthermore, data on
the risk factors associated with HCV infection and HCVgenotypes
were also extracted if available. Discrepancies in data extracted
were resolved through discussions with a third reviewer (M.E.).
Ethical considerations
As this study was a meta-analysis of published studies and
did not include the collection of individual patient data, no
specific ethics approval was needed.
Statistical analysis
We used the total number of tested persons and the number
of positive results (serology or PCR) to calculate the pre-
valence estimate and exact 95% confidence intervals (95%
CI). We derived study weights from the width of the 95% CI.
We combined estimates of the prevalence of HIV/HCV co-
infection by country using random-effects meta-analysis. We
analyzed the prevalence of co-infection stratified by the type
of test used: anti-HCV antibody tests (standard serological
tests and rapid tests) and PCR. Countries were classified into
low (B1.5%), moderate (1.53.5%) and high (3.5%)
prevalence, according to published definitions [15]. In order
to explain the potential heterogeneity obtained by pooling
prevalence estimates, we used random-effects meta-regression
to assess the association between HCV prevalence and
several study characteristics, including the type of study,
year of publication, setting, population and age. Variables
associated with anti-HCV antibody prevalence (pB0.1) were
included into the multivariable model.
Serology and PCR data on the prevalence of HIV/HCV
co-infection within the same study were available only for
few studies and countries. We used Poisson regression with
logarithmic link to estimate the ratio of prevalence estimates
based on serology and prevalence based on PCR from studies
with available data for both tests [16]. Analyses were con-
ducted separately by region (North Africa, West Africa,
Central Africa, East Africa and Southern Africa) and the
region-specific correction factor was applied to the country-
level estimates of serology-based prevalence to estimate the
prevalence of replicating HCV co-infection for countries with-
out PCR results. All statistical analyses were performed using
Stata software version 12.1 (College Station, TX).
Results
Study and participant characteristics
The PubMed and EMBASE searches identified 1163 publica-
tions. The screening of titles and abstracts resulted in the
selection of 276 potentially eligible studies, for which the
full-text articles were evaluated. Of these, 152 publications,
including three RCTs, 28 cohort studies and 121 cross-
sectional analyses met our inclusion criteria (Figure 1).
Six studies reported HCV prevalence estimates from two
or more populations. A detailed description of study char-
acteristics by publication and country is given in Supplemen-
tary Table 1. The studies originated from 35 African countries.
The number of studies per country ranged from one (Angola,
Burundi, Central African Republic, Equatorial Guinea, Gabon,
Guinea-Bissau, Lesotho, Namibia, Niger, Sudan, Tchad and
Zimbabwe) to 37 (Nigeria). Analyses for West Africa were
based on 65 studies, followed by East Africa (42), Southern
Africa (26), Central Africa (19) and North Africa (7) (Table 1).
In total, 24 studies (16%) included data from rural settings
and 36 (24%) from paediatric populations. The majority of
studies (84; 55%) were based on outpatients, followed by
blood donors (23; 15%) and pregnant women (22; 14%).
Eleven studies reported data from special populations, in-
cluding prisoners in Libya and Nigeria; PWID in Kenya, Libya,
Senegal and Tanzania; MSM in Tanzania and the Republic of
South Africa (RSA); female sex workers in Ethiopia and the
Democratic Republic of Congo (DRC) and forensic cases in RSA
(Supplementary Table 2).
Estimates of HIV/HCV co-infection prevalence from
different tests
In total, 187 HCV prevalence estimates were available, in-
cluding 158 from anti-HCV antibody tests. Among these,
101 were available from serology, including enzyme-linked
immunosorbent assay (ELISA) and enzyme immunoassay
(EIA), and 28 from rapid point-of-care tests. Although 29
studies confirmed serological test results with immunoblot
assays, full data from both test types were only available for
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10 of these. Twenty-nine studies showed PCR test results. The
number of estimates from HCV antibody tests by country
ranged from 1 to 35 (Nigeria). Cameroon and Nigeria were the
only countries to have PCR results from three different studies.
Median HCV viral load from PCR was reported in five studies
and ranged from 11,969 IU/mL inMorocco to 2,735,000 IU/mL
in Burkina Faso. In total, 18 studies from 14 countries (Morocco,
Burkina Faso, The Gambia, Ivory Coast, Nigeria, Cameroon,
Gabon, Guinea-Bissau, Ethiopia, Uganda, Lesotho, Malawi, RSA
and Zambia) reported HCV prevalence estimates from HCV-
antibody screening tests and PCR confirmation within the same
study population (Supplementary Table 3).
Prevalence of hepatitis C in HIV-infected patients,
by region and country
The prevalence of HIV/HCV infection according to HCV anti-
body screening tests (serology and rapid tests only) was 8.5%
(95% CI 6.910.1) (Figure 2a). The prevalence of anti-HCV
antibody positivity was highest in North Africa (42.3%, 95%
CI 4.180.5), followed by West Africa (6.9%, 95% CI 5.38.5),
Central Africa (6.5%, 95% CI 4.08.9), East Africa (6.3%, 95% CI
4.67.9) and southern Africa (3.3%, 95% CI 1.84.7). Libya
(90.1%), Tunisia (33.5%), Senegal (32.4%) and Angola (23.7%)
had the highest prevalence of anti-HCV positive HIV-infected
patients. For Libya, Tunisia and Senegal, the result relied on
studies in prisoners or in cohorts with high proportions of
PWID. The study from Angola included only 38 HIV-infected
patients and drug use was not assessed.
The overall estimate for confirmed, replicating HCV infec-
tion was 2.0% (95% CI 1.52.6) (Figure 2b). The prevalence
of HCV PCR-positivity was highest in Central Africa (8.0%, 95%
CI 5.010.9), followed by North Africa (3.8%, 95% CI 2.05.6),
West Africa (2.1%, 95% CI 1.13.2), East Africa (1.3%, 95%
CI 0.12.6) and southern Africa (0.8%, 95% CI 01.7).
Records identified
through database search:
PubMed: n= 638 
EMBASE: n= 958 
Total: n= 1,596 
Review of titles and
abstracts: n= 1,163
Review of full text articles
assessed: n= 276 
Studies included in
analyses: n= 152
Excluded:
Duplicates: n= 433 
Excluded::
Inclusion criteria not met: n= 885
No access to full paper: n= 2
Excluded::
Abstracts only: n= 33
Other reasons*: n= 91 
Figure 1. Flow Chart of identification of eligible studies (last search conducted on 3.3.16). *Other reasons were abstracts without published
full manuscripts (n33), no original studies (25), no specific estimates on HIV/HCV-coinfection (33), less than 20 HIV-infected patients (16),
insufficient information on HCV testing or study population (8), no reported estimates from the African continent (3), data based on a population
with liver disease only (1), reported data on patients included in another study (5).
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Mozambique (15.7%) and Cameroon (9.4%) had the highest
PCR-positivity prevalence. The estimate from Mozambique
relied on a single report, including 300 HIV-infected individuals
in an urban outpatient clinic where no injection drug use (IDU)
was reported. In Cameroon, three studies confirmed the high
prevalence of replicating HCV infections with minimal hetero-
geneity between studies (I-squared: 28.1%, p0.25).
There was little evidence that the prevalence of HCV-antibody
positivity depended on the type of setting (p0.79), age
group (p0.56), study design (p0.35) or year of publication
(p0.29) (Supplementary Table 4). The prevalence estimates
were higher in the group of studies performed in special
populations, which included analyses in prisoners and PWID
(Supplementary Table 2). However, when the nine studies
in special populations were excluded from the meta-regression,
the type of population did not influence the overall estimates
significantly (p0.22). Only one study from special populations
reported estimates from PCR results (PWID in Kenya). In meta-
analyses restricted to outpatient populations (n70 studies),
HCV prevalence was similar to the overall estimates (Supple-
mentary Figure 1).
Figure 3 shows the comparison between HCV prevalence
estimates from screening tests and PCR, by country, after the
exclusion of studies from special populations. The majority of
countries (16/29) were classified into the high-prevalence
group, according to HCV screening tests, whereas only five
of them (Botswana, Lesotho, Mali, Tchad and Zambia) were
included in the low-prevalence group (Figure 3a). However,
of 20 countries with available data, only five (Cameroon,
Gabon, Morocco, Mozambique, Nigeria and Togo) remained
in the high-prevalence group in the analysis based on PCR-
positivity (Figure 3b). Of note, the estimates for replicating
HCV infection prevalence in Morocco, Togo and Mozambique
each relied on a single, small study. When the region-specific
correction factor (Supplementary Table 3) was applied to
countries for which only serological data were available, im-
puted PCR prevalence estimates were obtained for 11 addi-
tional countries (Figure 3 and Supplementary Table 5).
Table 1. Study characteristics by region
Total (%) North Africa West Africa Central Africa East Africa Southern Africa
Number of study populations 159 7 65 19 42 26
Study design
RCT 4 (2.5) 0 1 1 1 1
Cohort 29 (18.2) 0 11 6 6 6
Cross-sectional 126 (79.3) 7 53 12 35 19
Year of publication
Before 2000 14 (8.8) 1 4 3 2 4
20002009 63 (39.6) 1 27 6 20 9
After 2009 82 (51.6) 5 34 10 20 13
Study population
Outpatients 84 (52.9) 4 36 11 19 14
Inpatients 11 (6.9) 0 2 0 5 4
Blood donors 23 (14.5) 0 12 3 5 3
Pregnant women 22 (13.8) 0 11 2 6 3
Community 8 (5.0) 1 2 2 3 0
Special populationsa 11 (6.9) 2 2 1 4 2
Age category
Adults 116 (76.3) 7 49 15 25 20
Children 9 (5.9) 0 3 1 5 0
Both 27 (18.8) 0 11 3 9 4
Setting
Urban 120 (83.3) 6 50 11 36 17
Rural 11 (7.7) 0 1 1 3 6
Both 13 (9.0) 0 8 3 2 0
Type of test
Serology 101 (54.0) 6 43 10 23 18
Rapid test 28 (15.0) 0 14 2 11 1
Immuno-blot 29 (15.5) 1 8 8 5 7
PCR 29 (15.5) 2 11 4 6 6
aTwo studies in prisoners in Libya and Nigeria, four studies in people who inject drugs (PWID) in Kenya, Libya, Senegal and Tanzania, one study in
men who have sex with men (MSM) and PWID in Tanzania, one study in MSM in the Republic of South Africa (RSA), two studies in female sex
workers in Ethiopia and the Democratic Republic of Congo and one study in forensic cases in RSA. (See Supplementary Table 2 for details.)
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HCV genotypes
Ten studies reported data on HCV genotypes. Nine of these
were from outpatient clinics in Cameroon, Ethiopia, Gambia,
Ghana, Guinea-Bissau, Nigeria, Morocco and Tunisia and one
from inpatients in Uganda. Of 74 samples analyzed, 39 (53%)
were of genotype 1, 18 (24%) of genotype 2 and 10 (14%)
genotype 4. Among the studies with available data, genotypes
3 (four samples) and 6 (one sample) were only described
in Morocco, and genotype 5 (two samples) in Ethiopia.
Figure 4 shows the genotype distribution for each country
with available data. Cameroon was the only country for which
two studies could be included. Genotype 1 was the most
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Figure 2. Meta-analysis of hepatitis C prevalence among HIV-infected individuals, by country, according to anti-HCV antibody tests (a) and
PCR (b) results.
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common one in all countries, except for Gambia, Ghana and
Guinea-Bissau, where genotype 2 was most prevalent, and
Ethiopia, where genotype 4 was most prevalent.
Discussion
Our meta-analysis aimed at assessing the prevalence of
hepatitis C in HIV-infected patients in Africa and describing
the differences in estimates between diagnostic tests. Overall,
152 studies, including 159 separate study populations across
35 countries, were included. We found a prevalence of anti-
HCV antibodies of 8.5%, with large differences across study
populations and countries. The prevalence of hepatitis C among
HIV-infected patients according to anti-HCV screening tests was
over four times higher than the estimates obtained for replicating
HCV infection, which was 2%. Only 19% of the studies included
reported data on PCR-confirmed HCV infections and 10 studies
showed HCV genotype distributions.
The overall anti-HCV antibody prevalence obtained in our
meta-analysis was higher than the estimates from the general
population, which ranged from 2.0% in East Africa to 2.8%
in West Africa according to a recent meta-analysis [15].
Globally, the high HCV prevalence in HIV-infected individuals
is driven by IDU and sexual transmission in MSM. In our
analysis, only two studies focused on MSM and five on PWID,
whereas IDU was only reported in eight studies, including
three from North Africa, two from Tanzania, one from Kenya,
one from Senegal and one from Nigeria. As a consequence,
it was very difficult to evaluate the impact of MSM or IDU
behaviour on the HCV seroprevalence from our results.
Although HIV epidemics in PWID have been well-described in
North Africa [17], data on PWID in sub-Saharan (SSA) are
scarce [6,18]. Nevertheless, it is considered that IDU is on the
rise in SSA, especially in large urban settings, and could
contribute to the spread of HCV infection [19]. Despite the
emergence of HCV infection epidemics in HIV-infected MSM
in industrialized settings [7,20], no study has reported an
increase in sexual transmission of HCV in HIV-infected MSM in
Africa to date. In meta-regression analyses, we found no
association between the main types of study populations
(including outpatients, inpatients, blood donors and pregnant
women) and anti-HCV prevalence.
The prevalence of HIV/HCV-coinfection was generally much
lower when only PCR-confirmed estimates were considered.
There are several potential explanations for the large dif-
ferences between HIV/HCV-coinfection prevalence estimates
obtained from anti-HCV antibody and PCR tests. Between
15 and 40% of HCV infections resolve without treatment,
depending on HIV status, sex, host genetic determinants as well
as HCV genotype [21,22]. However, as spontaneous clearance of
HCV infections cannot explain the four-fold difference between
the prevalence of anti-HCV positivity and replicating infections
found in our study, false-positive anti-HCV antibody results
seem to play a major role, as recognized previously [8]. Although
most studies report having used anti-HCV screening tests
Figure 3. Prevalence of hepatitis C among HIV-infected popula-
tions from (a) antibody tests (excluding immunoblots), (b) and PCR
tests. Combined estimates from random-effect meta-analysis (solid
fill) and imputed estimates from meta-regression (striped fill).
Studies in special populations were excluded for this analysis.
Figure 4. HCV genotype distribution in nine countries with
available data. The numbers in brackets are the number of samples
evaluated.
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according to the manufacturer’s instructions, the possibility
remains that defective test kits were used in some studies.
Alternatively, the presence of false-positive anti-HCV serologies
has been linked to cross-reactions with other types of antibodies.
The polyclonal B-cell activation following certain bacterial,
parasitic and viral infections typically produces antibodies that
are not specific to one type of infection [23]. In addition, cross-
reactions between these immune reagents and host antigens
also occur.Thus, immune responses to other infections as well as
the stimulation of auto-antibodies could explain false-positive
anti-HCV test results in certain settings. For instance, past schis-
tosomal infection, which is very common in many parts of SSA,
has been associated with false-positive anti-HCV results in Egypt
and Uganda [9,24]. Interestingly, among the countries with
available data from HCV antibody tests and PCR in our study,
Cameroon and Morocco, which have low schistosoma infection
prevalence [25], seemed to have the lowest proportion of false-
positive anti-HCV tests.
The evaluation of HCVgenotypes is central in understanding
the natural history, transmission chains and evolution of HCV
infection. Despite the very low number of samples assessed
for HCVgenotypes in the studies included in ourmeta-analysis,
the results seem to be in agreement with those from HIV-
uninfected cohorts reviewed in a recent meta-analysis [26].
Gower et al. showed that HCV genotype 4 predominated in
East and Central Africa, whereas genotypes 1 and 2 were most
prevalent inWest Africa. Among the seven countries with data
in the Gowan et al. study as well as in ours, genotype 1
predominated in Tunisia, Morocco and Nigeria in both meta-
analyses; genotype 2 was present in the majority of samples
from the Gambia, Ghana and Guinea-Bissau and genotype
4 was the most common one in Ethiopia. However, the com-
parison of our results with the study by Gowan et al. is limited
by their exclusion of studies with less than 1000 patients and
the low number of genotypes assessed in our study.
We reviewed an extensive body of literature without any
restriction on calendar period, language or age category, in
order to perform a comprehensive assessment of HCV pre-
valence in HIV-infected individuals in Africa. In order to com-
pare HCV prevalence estimates from different diagnostic
tests, we extracted detailed data on each test assessed in
every study. The most important limitation of our systematic
review was the paucity of data available from many African
countries and the limited number of patients included in a
large proportion of studies. For instance, 79 (50%) HIV/HCV
prevalence estimates relied on study populations of less than
200 HIV-infected individuals. Only 12 (34%) countries had
more than two studies included in the analyses, limiting the
generalizability of the HCV seroprevalence estimates in the
majority of countries. Furthermore, only a limited number
of studies confirmed their HCV antibody test results with
PCR and, in those that did, estimates for the different tests
performed were often not reported. Although very informa-
tive, our modelling of PCR-positivity prevalence estimates
does not replace original data for those countries in which no
original data were available. Finally, data on HCV genotypes
reported in this systematic review cannot be used to infer
general trends for specific countries or regions due to the very
limited number of samples assessed.
Conclusions
Our results show that despite the high HCV seroprevalence
in HIV-infected individuals in Africa, the prevalence of viremic
HCV infections and genotype distributions seem to be com-
parable to those from published data of the general population.
Our study underlines the potential over-estimation in HCV-
infection prevalence reported by many studies of HIV-infected
patients in settings endemic for other infections such as
schistosomiasis. In order to understand the differences in the
prevalence of replicating HCV infections across regions and
countries, future studies need to correlate the data from PCR
resultswith detailed assessments of risk factors for HCV infection,
including IDU and unsterile medical injections. Ways to over-
come the challenges posed by sub-optimal screening tests and
expensive PCR methods should be studied, including the imple-
mentation of HCV testing using dried blood spots as well as novel
diagnosticmethods such as hepatitis C core antigen tests [27] and
HCV antibody rapid test with better specificity [28].
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